Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BDRX
BDRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BDRX News
Biodexa Pharmaceuticals Reports Preliminary Results for 2025
3d ago
Newsfilter
Biodexa Pharmaceuticals Adjusts ADR Ratio
Mar 18 2026
seekingalpha
Biodexa Supports Life's a Polyp Foundation for FAP Patients
Mar 09 2026
Newsfilter
Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment
Feb 04 2026
Newsfilter
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
Jan 05 2026
NASDAQ.COM
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 16 2025
Benzinga
Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 09 2025
Benzinga
Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP
Nov 24 2025
Newsfilter
Biodexa Pharmaceuticals submits $100M shelf registration for versatile securities sales
Sep 26 2025
SeekingAlpha
Biodexa Pharmaceuticals Reports GAAP EPS of £0.00
Sep 12 2025
SeekingAlpha
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Receives Upgrade to Buy: Implications for the Stock
Sep 03 2025
NASDAQ.COM
Biodexa Reports Enrollment of Initial Patients in Key Phase 3 Serenta Trial for Familial Adenomatous Polyposis (FAP)
Aug 18 2025
Newsfilter
ADR Ratio Change Effective
Jul 31 2025
Newsfilter
Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
Jul 27 2025
TipRanks
ADR Ratio Change
Jul 15 2025
Newsfilter
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Jul 14 2025
Newsfilter
Show More News
